{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T04:48:57Z","timestamp":1705034937040},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"Abstract<\/jats:title>We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1<\/jats:italic> and BRCA2<\/jats:italic> variants, using follow-up data from 5453 BRCA1\/2<\/jats:italic> carriers from the Consortium of Investigators of Modifiers of BRCA1\/2<\/jats:italic> (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1<\/jats:italic> carrier patients overall (G\u00f6nen & Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1<\/jats:italic> variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2<\/jats:italic> variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2<\/jats:italic> carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2<\/jats:italic> status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.<\/jats:p>","DOI":"10.1038\/s41523-023-00546-x","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T19:02:09Z","timestamp":1683918129000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1\/2 variants"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-5895-1808","authenticated-orcid":false,"given":"Taru A.","family":"Muranen","sequence":"first","affiliation":[]},{"given":"Anna","family":"Morra","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-4185-8882","authenticated-orcid":false,"given":"Sofia","family":"Khan","sequence":"additional","affiliation":[]},{"given":"Daniel R.","family":"Barnes","sequence":"additional","affiliation":[]},{"given":"Manjeet K.","family":"Bolla","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-4591-1214","authenticated-orcid":false,"given":"Joe","family":"Dennis","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-5452-9933","authenticated-orcid":false,"given":"Renske","family":"Keeman","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-5756-6222","authenticated-orcid":false,"given":"Goska","family":"Leslie","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-3242-8477","authenticated-orcid":false,"given":"Michael T.","family":"Parsons","sequence":"additional","affiliation":[]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-0771-7752","authenticated-orcid":false,"given":"Thomas U.","family":"Ahearn","sequence":"additional","affiliation":[]},{"given":"Kristiina","family":"Aittom\u00e4ki","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-4226-6435","authenticated-orcid":false,"given":"Irene L.","family":"Andrulis","sequence":"additional","affiliation":[]},{"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-9714-104X","authenticated-orcid":false,"given":"Sabine","family":"Behrens","sequence":"additional","affiliation":[]},{"given":"Katarzyna","family":"Bialkowska","sequence":"additional","affiliation":[]},{"given":"Stig E.","family":"Bojesen","sequence":"additional","affiliation":[]},{"given":"Nicola J.","family":"Camp","sequence":"additional","affiliation":[]},{"given":"Jenny","family":"Chang-Claude","sequence":"additional","affiliation":[]},{"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-8023-2009","authenticated-orcid":false,"given":"Peter","family":"Devilee","sequence":"additional","affiliation":[]},{"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[]},{"given":"Alison M.","family":"Dunning","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Engel","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Gago-Dominguez","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-1033-2650","authenticated-orcid":false,"given":"Montserrat","family":"Garc\u00eda-Closas","sequence":"additional","affiliation":[]},{"given":"Anne-Marie","family":"Gerdes","sequence":"additional","affiliation":[]},{"given":"Gord","family":"Glendon","sequence":"additional","affiliation":[]},{"given":"Pascal","family":"Gu\u00e9nel","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Hahnen","sequence":"additional","affiliation":[]},{"given":"Ute","family":"Hamann","sequence":"additional","affiliation":[]},{"given":"Helen","family":"Hanson","sequence":"additional","affiliation":[]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[]},{"given":"Reiner","family":"Hoppe","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-1258-4843","authenticated-orcid":false,"given":"Louise","family":"Izatt","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-5650-0501","authenticated-orcid":false,"given":"Anna","family":"Jakubowska","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-4361-4657","authenticated-orcid":false,"given":"Paul A.","family":"James","sequence":"additional","affiliation":[]},{"given":"Vessela N.","family":"Kristensen","sequence":"additional","affiliation":[]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-9386-2416","authenticated-orcid":false,"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[]},{"given":"Arto","family":"Mannermaa","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Margolin","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-5053-0390","authenticated-orcid":false,"given":"Susan L.","family":"Neuhausen","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-6382-4678","authenticated-orcid":false,"given":"William G.","family":"Newman","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-6951-6855","authenticated-orcid":false,"given":"Paolo","family":"Peterlongo","sequence":"additional","affiliation":[]},{"given":"Kelly-Anne","family":"Phillips","sequence":"additional","affiliation":[]},{"given":"Miquel Angel","family":"Pujana","sequence":"additional","affiliation":[]},{"given":"Johanna","family":"Rantala","sequence":"additional","affiliation":[]},{"given":"Karina","family":"R\u00f8nlund","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0485-0120","authenticated-orcid":false,"given":"Emmanouil","family":"Saloustros","sequence":"additional","affiliation":[]},{"given":"Rita K.","family":"Schmutzler","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-9271-7778","authenticated-orcid":false,"given":"Maija","family":"Suvanto","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-1063-5352","authenticated-orcid":false,"given":"Yen Yen","family":"Tan","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-4896-5982","authenticated-orcid":false,"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[]},{"given":"Vishakha","family":"Tripathi","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Wappenschmidt","sequence":"additional","affiliation":[]},{"given":"Emily","family":"Zhao","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-2444-3247","authenticated-orcid":false,"given":"Douglas F.","family":"Easton","sequence":"additional","affiliation":[]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[]},{"given":"Georgia","family":"Chenevix-Trench","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-8494-732X","authenticated-orcid":false,"given":"Paul D. P.","family":"Pharoah","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-2228-429X","authenticated-orcid":false,"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[]},{"given":"Carl","family":"Blomqvist","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0916-2976","authenticated-orcid":false,"given":"Heli","family":"Nevanlinna","sequence":"additional","affiliation":[]},{"name":"HEBON investigators","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"546_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2464","volume":"12","author":"GC Wishart","year":"2010","unstructured":"Wishart, G. C. et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 12, R1 (2010).","journal-title":"Breast Cancer Res."},{"key":"546_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-017-0852-3","volume":"19","author":"FJ Candido Dos Reis","year":"2017","unstructured":"Candido Dos Reis, F. J. et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res. BCR 19, 58 (2017).","journal-title":"Breast Cancer Res. BCR"},{"key":"546_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejso.2011.02.001","volume":"37","author":"GC Wishart","year":"2011","unstructured":"Wishart, G. C. et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur. J. Surg. Oncol. 37, 411\u2013417 (2011).","journal-title":"Eur. J. Surg. Oncol."},{"key":"546_CR4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/bjc.2015.57","volume":"112","author":"T Maishman","year":"2015","unstructured":"Maishman, T. et al. An evaluation of the prognostic model PREDICT using the POSH cohort of women aged \u2a7d40 years at breast cancer diagnosis. Br. J. Cancer 112, 983\u2013991 (2015).","journal-title":"Br. J. Cancer"},{"key":"546_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/bjc.2015.466","volume":"114","author":"NA de Glas","year":"2016","unstructured":"de Glas, N. A. et al. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. Br. J. Cancer 114, 395\u2013400 (2016).","journal-title":"Br. J. Cancer"},{"key":"546_CR6","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1097\/MD.0000000000000593","volume":"94","author":"H-S Wong","year":"2015","unstructured":"Wong, H.-S. et al. The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer. Medicine 94, e593 (2015).","journal-title":"Medicine"},{"key":"546_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.03.015","volume":"78","author":"EG Engelhardt","year":"2017","unstructured":"Engelhardt, E. G. et al. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. Eur. J. Cancer 78, 37\u201344 (2017).","journal-title":"Eur. J. Cancer"},{"key":"546_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejca.2017.09.031","volume":"86","author":"MC van Maaren","year":"2017","unstructured":"van Maaren, M. C. et al. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. Eur. J. Cancer 86, 364\u2013372 (2017).","journal-title":"Eur. J. Cancer"},{"key":"546_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2022.06.011","volume":"173","author":"I Grootes","year":"2022","unstructured":"Grootes, I. et al. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. Eur. J. Cancer 173, 178\u2013193 (2022).","journal-title":"Eur. J. Cancer"},{"key":"546_CR10","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Jama 317, 2402\u20132416 (2017).","journal-title":"Jama"},{"key":"546_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/bcr953","volume":"7","author":"H Eerola","year":"2005","unstructured":"Eerola, H. et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. BCR 7, 93 (2005).","journal-title":"Breast Cancer Res. BCR"},{"key":"546_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat, N. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol. Biomark. Prev. 21, 134\u2013147 (2012).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"546_CR13","doi-asserted-by":"publisher","unstructured":"Mavaddat, N. et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6744 (2022).","DOI":"10.1001\/jamaoncol.2021.6744"},{"key":"546_CR14","doi-asserted-by":"publisher","first-page":"e0120189","DOI":"10.1371\/journal.pone.0120189","volume":"10","author":"AJ van den Broek","year":"2015","unstructured":"van den Broek, A. J., Schmidt, M. K., van\u2019t Veer, L. J., Tollenaar, R. A. E. M. & van Leeuwen, F. E. Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what\u2019s the evidence? A systematic review with meta-analysis. PLoS ONE 10, e0120189 (2015).","journal-title":"PLoS ONE"},{"key":"546_CR15","doi-asserted-by":"publisher","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","volume":"95","author":"Z Baretta","year":"2016","unstructured":"Baretta, Z., Mocellin, S., Goldin, E., Olopade, O. I. & Huo, D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine 95, e4975 (2016).","journal-title":"Medicine"},{"key":"546_CR16","doi-asserted-by":"publisher","first-page":"e0154789","DOI":"10.1371\/journal.pone.0154789","volume":"11","author":"AJ Templeton","year":"2016","unstructured":"Templeton, A. J. et al. Interaction between hormonal receptor status, age and survival in patients with BRCA1\/2 germline mutations: a systematic review and meta-regression. PLoS ONE 11, e0154789 (2016).","journal-title":"PLoS ONE"},{"key":"546_CR17","doi-asserted-by":"publisher","first-page":"djw329","DOI":"10.1093\/jnci\/djw329","volume":"109","author":"MK Schmidt","year":"2017","unstructured":"Schmidt, M. K. et al. Breast cancer survival of BRCA1\/BRCA2 mutation carriers in a hospital-based cohort of young women. J. Natl Cancer Inst. 109, djw329 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"546_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajhg.2023.02.003","volume":"110","author":"A Morra","year":"2023","unstructured":"Morra, A. et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am. J. Hum. Genet. 110, 1\u201312 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"546_CR19","doi-asserted-by":"publisher","unstructured":"Vocka, M. et al. Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1\/BRCA2 mutation carriers versus non-carriers. Cancers 11, https:\/\/doi.org\/10.3390\/cancers11060738 (2019).","DOI":"10.3390\/cancers11060738"},{"key":"546_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/bjc.2016.249","volume":"115","author":"JG Jonasson","year":"2016","unstructured":"Jonasson, J. G. et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br. J. Cancer 115, 776\u2013783 (2016).","journal-title":"Br. J. Cancer"},{"key":"546_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10549-013-2637-4","volume":"140","author":"L Tryggvadottir","year":"2013","unstructured":"Tryggvadottir, L. et al. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res. Treat. 140, 375\u2013384 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"546_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41416-019-0376-y","volume":"120","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe, K. et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br. J. Cancer 120, 398\u2013403 (2019).","journal-title":"Br. J. Cancer"},{"key":"546_CR23","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/s41416-020-01056-4","volume":"123","author":"EJ Olafsdottir","year":"2020","unstructured":"Olafsdottir, E. J. et al. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. Br. J. Cancer 123, 1608\u20131615 (2020).","journal-title":"Br. J. Cancer"},{"key":"546_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto, R. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432\u2013444 (2012).","journal-title":"Lancet"},{"key":"546_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771\u2013784 (2011).","journal-title":"Lancet"},{"key":"546_CR26","doi-asserted-by":"publisher","first-page":"djw314","DOI":"10.1093\/jnci\/djw314","volume":"109","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data. J. Natl Cancer Inst. 109, djw314 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"546_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","volume":"377","author":"MP Coleman","year":"2011","unstructured":"Coleman, M. P. et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995\u20132007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377, 127\u2013138 (2011).","journal-title":"Lancet"},{"key":"546_CR28","doi-asserted-by":"publisher","unstructured":"Nones, K. et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz132 (2019).","DOI":"10.1093\/annonc\/mdz132"},{"key":"546_CR29","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J. Clin. Oncol. 38, 2080\u20132106 (2020).","journal-title":"J. Clin. Oncol."},{"key":"546_CR30","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"546_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41571-021-00544-7","volume":"18","author":"SA Narod","year":"2021","unstructured":"Narod, S. A. Adjuvant olaparib\u2014should all patients with breast cancer have genetic testing? Nat. Rev. Clin. Oncol. 18, 607\u2013608 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"546_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","volume":"1","author":"K Metcalfe","year":"2015","unstructured":"Metcalfe, K. et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 1, 306\u2013313 (2015).","journal-title":"JAMA Oncol."},{"key":"546_CR33","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41416-020-01164-1","volume":"124","author":"DG Evans","year":"2021","unstructured":"Evans, D. G. et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. Br. J. Cancer 124, 1524\u20131532 (2021).","journal-title":"Br. J. Cancer"},{"key":"546_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10549-017-4605-x","volume":"168","author":"SA Narod","year":"2018","unstructured":"Narod, S. A. et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res. Treat. 168, 513\u2013521 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"546_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"BCA Consortium","year":"2021","unstructured":"Consortium, B. C. A. et al. Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428\u2013439 (2021).","journal-title":"N. Engl. J. Med."},{"key":"546_CR36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/humu.23818","volume":"40","author":"MT Parsons","year":"2019","unstructured":"Parsons, M. T. et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: an ENIGMA resource to support clinical variant classification. Hum. Mutat. 40, 1557\u20131578 (2019).","journal-title":"Hum. Mutat."},{"key":"546_CR37","unstructured":"Team, R. C. R: A language and environment for statistical computing (2018)."},{"key":"546_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"Svan Buuren","year":"2011","unstructured":"Buuren, Svan & Groothuis-Oudshoorn, K. mice: Multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1\u201367 (2011).","journal-title":"J. Stat. Softw."},{"key":"546_CR39","unstructured":"Rubin, D. B. Multiple Imputation for Nonresponse in Surveys (John Wiley & Sons, 2004)."},{"key":"546_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-57","volume":"9","author":"A Marshall","year":"2009","unstructured":"Marshall, A., Altman, D. G., Holder, R. L. & Royston, P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med. Res. Methodol. 9, 57 (2009).","journal-title":"BMC Med. Res. Methodol."},{"key":"546_CR41","doi-asserted-by":"crossref","unstructured":"Therneau, T. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, 2000).","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"546_CR42","unstructured":"Therneau, T. A Package for Survival Analysis in S. version 2.38 (2015)."},{"key":"546_CR43","unstructured":"Mo, Q., G\u00f6nen, M. & Heller, G. CPE: Concordance Probability Estimates in Survival Analysis. R package (2018)."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-023-00546-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-023-00546-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-023-00546-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T19:02:47Z","timestamp":1683918167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-023-00546-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["546"],"URL":"http:\/\/dx.doi.org\/10.1038\/s41523-023-00546-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2269143\/v1","asserted-by":"object"}]},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":["Pharmacology (medical)","Radiology, Nuclear Medicine and imaging","Oncology"],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.Ne. has had an AstraZeneca consultancy. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}